Opendata, web and dolomites

ANTHEM SIGNED

ANTHEM: A Novel Tolerogenic vaccine for the treatment of antibodies in HaEMophilia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ANTHEM project word cloud

Explore the words cloud of the ANTHEM project. It provides you a very rough idea of what is the project "ANTHEM" about.

vulnerable    haemophilia    morbidities    eradicate    basis    blood    efficacy    burden    mean    strategic    117    crippling    heavy    technologies    establishing    constitute    budgets    safe    dendritic    resistance    trial    tolerogenic    cells    kols    exerts    reaching    antibodies    accelerated    pressing    lifetime    body    reprogrammed    adverse    supports    create    validate    annual    transferred    mortality    35    protein    eur    overcome    lies    commercialisation    iti    na    therapy    patient    standard    person    situation    strategy    care    outside    back    data    induction    clotting    date    emphasise    tolerance    clinical    realize    million    leads    capacity    treatment    safety    neutralizing    platform    humans    healthcare    patients    preliminary    utilizes    idogen    prevalence    failed    viii    haematologists    policy    uses    performed    consequence    counteract    substantially    treat    arthropathy    vaccine    cornerstone    3012    mechanism    health    serious    immune    reactions   

Project "ANTHEM" data sheet

The following table provides information about the project.

Coordinator
IDOGEN AB 

Organization address
address: SCHEELEVAGEN 2
city: LUND
postcode: 223 81
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://idogen.com
 Total cost 2˙868˙734 €
 EC max contribution 2˙868˙734 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IDOGEN AB SE (LUND) coordinator 2˙868˙734.00

Map

 Project objective

This project will develop and validate IN-3012, a novel tolerogenic vaccine that utilizes a person’s own cells to treat neutralizing antibodies (NA) in Haemophilia A patients who have failed immune tolerance induction (ITI). Haemophilia A patients are given the blood clotting protein, factor VIII as standard of care. However, a serious consequence is the development of NA towards factor VIII leading to therapy resistance. This leads to crippling arthropathy, other morbidities and high mortality. ITI is the most used treatment of this condition but 35% of patients do not respond and are in a vulnerable situation.

Haematologists and KOLs emphasise the pressing need for safe and effective technologies to overcome NA in Haemophilia A, which is not possible today. The estimated mean annual cost of a Haemophilia patient in Europe is over EUR 117,000 EUR with the mean lifetime cost reaching EUR 7.8 million. This is substantially higher in patients who have failed ITI. Therefore, while this condition has low prevalence, it exerts heavy burden on healthcare budgets and is thus a top EU health policy priority.

Idogen’s technology platform allows cells from the patient’s blood to be reprogrammed outside the body to dendritic cells with the capacity to specifically counteract adverse immune reactions. The reprogrammed cells are transferred back to the patient. IN-3012 uses this mechanism to create tolerance to factor VIII.

The research performed to date strongly supports the vaccine’s potential to eradicate NA. The proposed project will bring IN-3012 through a Phase I/II clinical trial in humans. The safety and preliminary efficacy data will constitute the basis for further clinical development and commercialisation of the product. Idogen’s strategic focus lies in establishing IN-3012 as a novel treatment in Haemophilia A patients having failed ITI. This will constitute the cornerstone of Idogen’s accelerated growth. This project is the key step to realize the strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANTHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More